Sentence examples for mice we treated from inspiring English sources

To determine if we could reproduce the PRKO high bone mass phenotype in female WT mice, we treated female WT mice with RU486 from one to three months of age.

To evaluate whether the murine wild type p53 is intact in the lung cancers collected from the SPC-p53 (273H) transgenic mice, we treated the transgenic mice using a 137Cesium γ-source at a dose of 5Gy/mouse.

To determine whether TNF-α mediates exacerbated inflammation in Notch-deficient mice, we treated WT, Notch3 –/–, and Notch4 –/– mice with the TNF-α inhibitor etanercept before ozone exposure.

In order to evaluate the protective effects of this antioxidant in Sod1−/− mice, we treated them with VC to try to rescue the organ phenotypes.

In order to evaluate the impact of chronic oxidative stress in obesity predisposition of TP53INP1 KO mice, we treated the mice with NAC at the starting of HFD.

To determine if the phenotype would also occur in adult mice, we treated 16 week old virgin IKMV and control females with dox for 10 days.

To determine whether HS+MES ameliorates hyperglycemia in these high fat-fed mice, we sham treated or treated this group of mice with HS+MES for 10 min twice a week for 10 weeks.

To investigate the effect of TGFαL3SEAD227A on mouse survival, we treated mice with 60 pmol of fusion drug identically when the tumours' length exceeded 1 cm.

To assess the role of brivaracetam in APP/PS1 mouse phenotypes, we treated 13-month-old mice chronically, measuring the effect of drug therapy on spatial memory, Aβ levels, synapse loss and hippocampal calbindin D28 immunoreactivity.

To assess the role of ethosuximide in APP/PS1 mouse phenotypes, we treated 16-month-old mice chronically (45 days), followed by measurements of spatial memory, APP metabolism and Aβ levels, synapse loss, and hippocampal calbindin D28 immunoreactivity.

To assess the effects of aPL antibodies in mice depleted of granulocytes, we treated pregnant mice with anti-mouse Ly-6G (α-Gr) or control murine IgG2K prior to administration of human IgG containing aPL (aPL-IgG).